Form 4: Bristol-Myers Squibb Executive David Elkins Reports Stock Transactions

EVP and CFO David Elkins reports acquisition and disposal of Bristol-Myers Squibb common stock and derivative securities, including vesting of market share units and performance shares.

Summary

• David V. Elkins, EVP and Chief Financial Officer of Bristol-Myers Squibb, filed a Form 4 detailing changes in beneficial ownership of company stock.
• The report includes transactions from March 10, 2025, involving common stock and derivative securities such as market share units and performance shares.
• Elkins acquired shares through the vesting of market share units and distribution of performance shares earned under the 2022-2024 Long-Term Performance Award.
• He also disposed of shares to cover tax obligations upon vesting of awards.
• The reported transactions resulted in adjustments to Elkins' holdings of both common stock and derivative securities.
• Some market share units convert into common stock based on a payout factor tied to the company's stock price performance.
• Performance shares convert into common stock upon distribution, subject to performance results certified by the Board.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a routine filing related to executive compensation. The vesting of shares suggests performance targets were met, which is mildly positive, but the sale of shares for tax purposes is a neutral event.

Positives

• The vesting of market share units and distribution of performance shares indicate that certain performance targets were met, which is a positive sign for the company's performance.
• The increase in Elkins' direct ownership of common stock to 223,379 shares could be interpreted as a sign of confidence in the company's future prospects.

Negatives

• The disposal of shares to cover tax obligations, while a normal occurrence, does represent a reduction in Elkins' holdings.

Future Outlook

Future vesting of market share units and distribution of performance shares are subject to continued employment and achievement of performance targets.

Industry Context

Form 4 filings are a routine part of executive compensation and provide transparency into the alignment of management's interests with those of shareholders.

Comparison to Industry Standards

• Executive compensation packages at large pharmaceutical companies like Bristol-Myers Squibb typically include a mix of salary, stock options, restricted stock units, and performance-based incentives.
• Companies like Johnson & Johnson, Pfizer, and Merck also utilize similar long-term incentive plans to align executive compensation with shareholder value creation.
• The vesting schedules and performance metrics used in these plans are often benchmarked against industry peers to ensure competitiveness and effectiveness.

Stakeholder Impact

• The vesting of shares and distribution of performance awards can be seen as a positive sign by shareholders, indicating that management is incentivized to improve company performance.
• Employees may be impacted by the overall performance of the company, which affects the value of their stock-based compensation.

Key Dates